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Prevalence and Seroprevalence of Low-Risk Human 
Papillomavirus in Korean Women 
Little is known about the prevalence and seroprevalence of low-risk human papillomavirus 
(HPV) and the risk factors for HPV infection in Korean women. We determined the 
prevalence of low-risk HPV among 902 women aged 20-59 yr and the seroprevalence of 
low-risk HPV subtypes 6 and 11 among 1,094 women aged 9-59 yr in the general 
population. Genital low-risk HPV DNA was assessed by liquid hybridization and polymerase 
chain reaction. Antibody titers against HPV 6 and 11 were measured by a multiplexed 
competitive luminex technique. The prevalence of genital low-risk HPV was 4.9%. It 
reached its highest peak of 10.3% at 20-29 yr of age and a second peak of 3.2% at 50-59 
yr of age. The seroprevalence of HPV 6 or 11 was 9.4%. It reached its highest peak of 
12.7% at 25-29 yr of age and a second peak of 12.3% at 50-59 yr of age. In multivariable 
analysis, the number of lifetime sexual partners and past history of sexually transmitted 
diseases were associated with the seroprevalence but not prevalence of HPV. It is suggested 
that younger women should receive prophylactic HPV vaccination before they become 
sexually active and exposed to HPV in their 20s. This study provides baseline data for 
developing HPV vaccination programs and monitoring vaccine efficacy in Korea.
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INTRODUCTION
Human papillomavirus (HPV) is the most common sexually 
transmitted infection. In one study, approximately half of the 
women without HPV infection became infected with HPV with-
in 3 yr after initiating sexual activity (1). Currently, more than 
100 different HPV subtypes have been identified, which mostly 
infect genital epithelial cells. HPV subtypes are divided broadly 
into two groups according to their epidemiological association 
with cervical cancer. The low-risk HPV group, including HPV 
subtypes 6 and 11, is associated with benign lesions, genital warts 
or recurrent respiratory papillomatosis (2). The high-risk HPV 
group, including HPV subtypes 16 and 18, induces precancer-
ous lesions such as cervical intraepithelial neoplasia (CIN), cer-
vical cancer or ano-genital cancer (3, 4). 
 After sexual contact, genital warts may occur in the uterine 
cervix, vagina, vulva, anus and oral cavity. Approximately 90% 
of genital warts are related to low-risk HPV types 6 and 11 (5-7). 
The incidence of genital warts has gradually increased since the 
1950s (6), and has become a major cause of nononcogenic HPV-
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related morbidity. In addition, low grade squamous intraepi-
thelial lesions are associated with not only high-risk HPV infec-
tion but also low-risk HPV 6 and 11 infection. 
 Our current epidemiological knowledge of HPV infection is 
based on the genital HPV DNA test which only identifies the 
current HPV infection (8). In addition, the HPV DNA test has 
been applied limitedly because of the difficulty of collecting 
samples from males and the reluctance to gynecologic exami-
nation among females (9-11). In contrast, serum antibody to 
HPV is a useful, although not perfect, complementary marker 
reflecting cumulative HPV exposure (8, 12, 13). 
 In the general population of Korea, very little data exist on 
the epidemiology of low-risk HPV 6 and 11, which are two of 
the four types targeted by the quadrivalent HPV vaccine (10, 14, 
15). We estimated the prevalence and seroprevalence of low-
risk HPV infection in Korean women in order to help establish 
vaccine policy specific to the characteristics of Korean women 
and assess vaccine efficacy.
MATERIALS AND METHODS
Study subjects
We conducted a survey of the prevalence and seroprevalence 
of low-risk HPV in Korean women between July 2008 and May 
2009. A total of 1,143 women, 9-59 yr of age, who visited our in-
stitutions for a regular medical check-up were eligible for this 
study. All study samples were obtained using a complex, strati-
fied, multistage probability cluster design in order to select a 
nationally representative sample. For females from 9 to 19 yr of 
age, the low-risk HPV serologic test was performed without a 
questionnaire study or a genital HPV DNA test in light of the 
relatively late age of sexual debut and conservative sexual cul-
ture found in Korea. Females 20-59 yr of age were asked to fill 
out a self-reporting questionnaire containing questions relating 
to socio-demographic characteristics and lifestyle habits asso-
ciated with HPV infection, such as sexual behavior, history of 
sexually transmitted disease (STD), usage of tobacco and usage 
of oral contraceptives. 
 Of a total of 1,143 women, the prevalence of low-risk HPV was 
analyzed in a total of 902 women aged 20-59 yr. This excludes 
241 women; one who did not agree to the study, four who did 
not respond to the questionnaire, eight whose results regarding 
Hybrid Capture II (HC II) were missing and 228 who were 9-19 yr 
of age. Of the 1,130 women 9-59 yr of age, comprised of the 228 
who were 9-19 yr of age along with the 902 who were 20-59 yr of 
age, an analysis was performed for the seroprevalence of low-risk 
HPV in a total of 1,094 females. This excludes 36 women 20 yr of 
age or older from whom serum samples could not be collected. 
Specimen collection 
Cervicovaginal cells were collected from 902 women 20-59 yr 
of age using a Cytobrush (Cervibrush, Cell-Path, Herte, United 
Kingdom). These cells were collected in an Eppendrof tube that 
contained 20 mL of phosphate buffer solution (PBS). Blood sam-
ples of 10 mL were collected from each of 1,094 women 9-59 yr 
of age using the vacutainer system. Blood samples were centri-
fuged at 1,500 g for 10 minutes and the serum was separated 
from the cells. All samples were transported to a central labora-
tory and stored at -70°C until processing.
Low-risk HPV DNA testing by HC II 
To confirm low-risk HPV group (consisting of HPV subtypes 6, 
11, 42, 43, 44) infection and viral load, cervicovaginal cells were 
harvested using a dacron swab, added to the collection kit (Di-
gene, Gaithersburg, MD, USA) and stored at -20°C until analysis. 
RNA probes of low-risk HPV were hybridized with denatured, 
single-stranded DNA. This reaction mixture was transferred to 
a tube coated with anti-DNA-RNA hybrid antibodies. The im-
mobilized hybrids were then incubated with an alkaline phos-
phatase-conjugated antihybrid monoclonal antibody. After rins-
ing, these reactants were treated with Lumi-Phospho 530, which 
reacts to alkaline phosphatase, a dioxetane-based chemilumi-
nescent substrate. The light generated by the reaction was mea-
sured by luminometer and the intensity was recorded using 
units which were relative to the reaction. The relative unit for 
the light intensity was defined as the degree of illumination rel-
ative to the positive control group. A positive cutoff value was 
set at 1 pg HPV DNA per milliliter in each specimen. 
Low-risk HPV DNA testing by polymerase chain reaction 
(PCR)
For typing of low-risk HPV subtypes 6 and 11, DNA was extract-
ed using the Qiagen DNA extraction kit (Qiagen, Valencia, CA, 
USA). β-globin PCR was performed to check the DNA quality. 
GP5+/6+ primer was used on all of the β-globin PCR positive 
samples to confirm whether they were positive for low-risk HPV 
subtypes 6 and 11. Samples testing positive for low-risk HPV 
were examined by PCR using HPV 6 and 11 primer to determine 
the specific subtype. 
Low-risk HPV serologic test
The antibodies to low-risk HPV subtypes 6 and 11 were mea-
sured by Merck and Co. Inc., using a multiplexed competitive 
Luminex® assay. The antibody titration method was measured 
according to the HPV antibody measurement method reported 
by Opalka et al. in 2003 (16), and reported in milli-Merck units 
per mL. The monoclonal antibodies used in the HPV multi-
plexed competitive Luminex assay included H6.M48 and K11.
B2 for low-risk HPV subtypes 6 and 11, respectively. Cutoff val-
ues for HPV seropositivity were at least 20 and at least 16 mMU/
mL for HPV subtypes 6 and 11, respectively (17).
Kim M-A, et al. • Low-Risk HPV Infection in Korean Women
924  http://jkms.org http://dx.doi.org/10.3346/jkms.2012.27.8.922
Statistical analysis
Odds ratios (ORs) and corresponding 95% confidence intervals 
(CIs) were calculated using unconditional multiple logistic re-
gression to assess the associations between HPV DNA/seropos-
itivity and demographic and behavioral characteristics. For all 
analyses, a significance level of P < 0.05 was chosen.
Ethics statement
All participants signed and submitted an informed consent for 
this study. The study protocol was approved by the institutional 
review board of Gangnam Severance Hospital (IRB No. 3-2008-
0097), Seoul.
RESULTS
Table 1 shows the overall and age-specific prevalence of low-
risk HPV in the study population. Of the 902 Korean women 20-
59 yr of age that were tested for prevalence of HPV, 4.9% (44 of 
902) were shown to be positive for low-risk HPV DNA. The age-
standardized prevalence, calculated by applying the female 
population given by the National Statistics Office for Korea in 
2008, was shown to be 4.9% (95% CI 2.3-7.6). The prevalence of 
low-risk HPV reached its highest peak of 10.3% (95% CI 6.2-14.5) 
among females 20-29 yr of age and decreased thereafter. It then 
reached a second peak of 3.2% (95% CI 0.9-5.6) among females 
50-59 yr of age.
 Of the 44 HC II positive samples, only 8 (18.2%) had subtypes 
confirmed by PCR; the subtypes of the remaining 36 samples 
were not confirmed. Of the 8 samples whose subtypes were con-
firmed, 8 samples (18.2%) were positive for HPV 6 and 2 sam-
ples (4.5%) were additionally positive for HPV 11, meaning there 
was simultaneous co-infection with HPV 6. The type-specific 
prevalence for HPV 6 and HPV 11 were 0.9% and 0.2%, respec-
tively (data not shown). 
 Of 1,094 females 9-59 yr of age tested for seroprevalence of 
HPV, the seroprevalence of either low-risk HPV subtypes 6 or 
11 was 9.4% (95% CI 7.7-11.3), and the age-standardized serop-
revalence was shown to be 9.6% (95% CI 7.8-11.4). The age-spe-
cific seroprevalence of low-risk HPV reached its highest peak 
of 12.7% (95% CI 7.7-19.3) among females 25-29 yr of age. It de-
creased thereafter but reached a second peak of 12.3% (95% CI 
8.2-17.6) among females 50 to 59 yr of age (Fig. 1). The type-
specific seroprevalences of low-risk HPV are shown in Table 2. 
HPV 6 seroprevalence was 8.1% (95% CI 6.6-9.9), and HPV 11 
seroprevalence was 3.9% (95% CI 2.9-5.3). Peak seroprevalence 
occurred in the 30-39 yr-old age group for HPV 6 (11.4%, 95% 
CI 7.5-16.3) and in the 25-29 yr-old age group for HPV 11 (7.0%, 
Fig. 1. Seroprevalence for low-risk HPV types in 1,094 Korean women by age group.
Se
ro
pr
ev
al
en
ce
 o
f l
ow
 ri
sk
 H
PV
 (%
)
Age (yr)
 09-14 15-19 20-24 25-29 30-39 40-49 50-59
14.0
12.0
10.0
8.0
6.0
4.0
2.0
0.0
HPV 6 or 11
HPV 6
HPV 11
HPV 6 and 11
Table 1. Prevalence of genital low-risk HPV in 902 Korean women by age group
Age (yr)
No. of  
subjects
No. of subjects
Low-risk HPV (+) 
Prevalence of Low-risk 
HPV, % (95% CI)
20-29 203 21 10.3 (6.2-14.5)
30-39 235 10 4.3 (1.7-6.8)
40-49 246   6 2.4 (0.5-4.4)
50-59 218   7 3.2 (0.9-5.6)
Overall 902 44 4.9 (3.5-6.3)
Age-standardized
   prevalence*
4.9 (2.3-7.6)
*Prevalence was standardized by age on the basis of the female population of Korea 
in 2008. HPV, human papillomavirus; CI, confidence interval.
Table 2. Seroprevalence for low-risk HPV types in 1,094 Korean women by age group
Age (yr) No. of subjects 
Positive rates for, % (95% CI)
HPV 6 HPV 11 HPV 6 or 11 HPV 6 and 11
9-14 150 2.0 (0.4-5.7) 1.3 (0.2-4.7) 2.0 (0.4-5.7) 1.3 (0.2-4.7)
15-19 78 2.6 (0.3-9.0) 2.6 (0.3-9.0) 3.8 (0.8-10.8) 1.3 (0.03-6.9)
20-24 55 7.3 (2.0-17.6) 5.5 (1.1-15.1) 9.1 (3.0-19.9) 3.6 (0.4-12.5)
25-29 142 10.6 (6.0-16.8) 7.0 (3.4-12.6) 12.7 (7.7-19.3) 4.9 (2.0-9.9)
30-39 220 11.4 (7.5-16.3) 3.6 (1.6-7.0) 11.4 (7.5-16.3) 3.6 (1.6-7.0)
40-49 239 7.9 (4.8-12.1) 3.3 (1.5-6.5) 9.6 (6.2-14.1) 1.7 (0.4-4.2)
50-59 210 10.0 (6.3-14.9) 4.8 (2.3-8.6) 12.3 (8.2-17.6) 2.4 (0.8-5.5)
Overall 1,094 8.1 (6.6-9.9) 3.9 (2.9-5.3) 9.4 (7.7-11.3) 2.6 (1.8-3.8)
Age-standardized prevalence* 8.3 (6.6-10.0) 4.0 (2.8-5.2) 9.6 (7.8-11.4) 2.7 (1.7-3.7)
*Prevalence was standardized by age on the basis of the female population of Korea in 2008. HPV, human papillomavirus; CI, confidence interval.
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95% CI 3.4-12.6). Just like the overall seroprevalence of low-risk 
HPV, the type-specific seroprevalences for HPV 6 and 11 reached 
second peaks in the 50-59 yr-old age group. Seropositivity for 
both low-risk HPV 6 and 11 was rare (2.6%, 95% CI 1.8-3.8) and 
reached its highest peak among females aged 25-29 yr. 
 Table 3 presents the concordance between low-risk HPV DNA 
positivity and seropositivity. A total of 868 women aged 20-59 yr 
were tested with both HC II for the presence of low-risk HPV 
DNA and a HPV serologic test for seropositivity of low-risk HPV 
subtypes 6 and 11. Of the 44 HC II positive samples, only 8 had 
subtypes confirmed by PCR. Among females who were PCR-
positive for HPV 6 and 11, the proportions who were also sero-
positive to the respective type were 1/8 (12.5%) and 0/2 (0%), 
respectively. Among PCR-negative for HPV 6 and 11, the pro-
portions that were seropositive to the respective type were 83/ 
860 (9.7%) and 39/866 (4.5%), respectively. 
 We analyzed the relationship between socio-demographic 
and behavioral characteristics and the seroprevalence of low-
risk HPV. Seroprevalence of low-risk HPV was significantly as-
sociated with the lifetime number of sexual partners and past 
Table 3. Concordance between genital low-risk HPV 6 and 11 infection and serum 
antibodies among Korean women
HPV DNA by PCR
Serum antibodies
Antibody-negative,  
n (%)
Antibody-positive  
for the same type to HPV  
DNA, n (%)
HPV 6
   Negative
   Positive
 
777 (90.3)
    7 (87.5)
 
83 (9.7)
    1 (12.5)
HPV 11
   Negative
   Positive
 
827 (95.5)
   2 (100)
 
39 (4.5)
  0 (0.0)
HPV, human papillomavirus; CI, confidence interval.
Table 4. Odds ratios and 95% confidence intervals according to risk factors of seropositivity for low-risk HPV (HPV 6 or 11) in Korean women
Risk factors No.
Low-Risk HPV  
Seropositive, n (%)
OR (95% CI)
Adjusted OR*  
(95% CI)
P  value
Age (yr)
   9-14
   15-19
   20-24
   25-29
   30-39
   40-49
   50-59
 
150
78
55
142
220
239
210
 
  3 (2.0)
  3 (3.8)
  5 (9.1)
  18 (12.7)
  25 (11.4)
23 (9.6)
  26 (12.4)
 
-
-
Reference
1.5 (0.5-4.1)
1.3 (0.5-3.5)
1.1 (0.4-2.9)
1.4 (0.5-3.9)
 
-
-
Reference
  7.0 (0.7-67.3)
  4.0 (0.4-42.4)
  3.8 (0.3-42.2)
  5.4 (0.5-60.6)
0.664
New sexual partner in recent 6 months
   No
   Yes
 
759
72
 
  79 (10.4)
  14 (19.4)
 
Reference
2.1 (1.1-3.9)
 
Reference
1.1 (0.4-3.2)
0.800
Lifetime number of sexual partners
   1
   2
   3 or more
 
578
101
108
 
50 (8.7)
10 (9.9)
  19 (17.6)
 
Reference
1.2 (0.6-2.4)
2.3 (1.3-4.0)
Reference
1.2 (0.5-2.6)
2.5 (1.1-5.6)
0.028
Age at sexual debut
   18 or younger
   19-24
   25 or older
 
40
454
291
 
  13 (32.5)
  46 (10.1)
24 (8.3)
 
  5.4 (2.4-12.0)
1.3 (0.7-2.1)
Reference
 
2.1 (0.6-7.0)
1.2 (0.6-2.2)
Reference
0.310
Tobacco use
   No
   Yes
 
795
45
 
  85 (10.7)
    9 (20.0)
 
Reference
  2.1 (0.97-4.5)
 
Reference
1.5 (0.5-4.3)
0.483
History of STDs
   No
   Yes
 
773
57
 
  78 (10.1)
  16 (28.1)
 
Reference)
3.5 (1.9-6.5)
 
Reference
3.6 (1.6-8.2)
0.001
Oral contraceptive use
   No
   Yes
 
699
118
  
69 (9.9)
  20 (17.0)
 
Reference
1.9 (1.1-3.2)
 
Reference
1.0 (0.5-2.2)
0.923
Marital status
   Married
   Others†
 
642
198
 
  69 (10.7)
  23 (11.6)
 
Reference
1.1 (0.7-1.7)
 
Reference
0.5 (0.2-1.3)
0.073
Education level
   Less than high school
   University or higher
 
434
409
 
  59 (13.6)
36 (8.8)
 
  1.6 (1.04-2.5)
Reference
 
0.8 (0.4-1.5)
Reference
0.570
Childbirth
   Never
   Ever
 
204
639
 
  22 (10.8)
  72 (11.3)
 
Reference
1.1 (0.6-1.7)
 
Reference
1.0 (0.3-2.8)
0.887
*Adjusted for age, new sexual partner in recent 6 months, lifetime number of sexual partners, age at sexual debut, tobacco use, history of STDs, oral contraceptive use, marital 
status, education level, and childbirth. †Single, divorced, separated or widowed. HPV, human papillomavirus; OR, odds ratio; CI, confidence interval; STDs, sexually transmitted 
diseases. 
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history of STD. The seroprevalence of low-risk HPV increased 
from 8.7% among females with 1 lifetime sexual partner to 17.6% 
among those with 3 lifetime sexual partners (P = 0.028). We 
also found that past history of STD was significantly associated 
with the seroprevalence of low-risk HPV (P = 0.001). The effects 
of the remaining risk factors were not statistically significant 
(Table 4).
DISCUSSION
This is the first study to describe the seroprevalence along with 
the prevalence of low-risk HPV in Korean women. The preva-
lence of genital low-risk HPV infection detected by HC II was 
shown to be 4.9% (the age-standardized prevalence was 4.9%). 
This is comparable to a low-risk HPV prevalence of 4.1% report-
ed by Shin et al. in 2003 (15) using the PCR method and lower 
than that reported in the United States (18). Low-risk HPV prev-
alence in men was 0%-43% in several studies and 2.6% in Korean 
university students (10). In regard to the age-specific prevalence 
of low-risk HPV, it reached its highest peak at 20-29 yr of age, 
and afterward, it showed a tendency to decrease, but reaching 
a second peak at 50-59 yr of age. This is similar to previously re-
ported results (19). The age-specific pattern we found can be 
explained by multiple factors. One possible explanation is that 
middle-aged women have new sexual partners as they become 
more sexually active, and thus the possibility of new HPV infec-
tion becomes high. Another is the reactivation of latent HPV in-
fection due to the deterioration of immunity as a result of hor-
monal deficiency during the perimenopausal period. Host fac-
tor such as immune-compromised status can play a role in the 
HPV infection (20). A third explanation is the cohort effect: prev-
alence appears to be high, but in reality patients were unaware 
of an infection that occurred in their 20s which was detected 
only from the results of tests performed later (19, 21, 22). 
 Concerning the distribution of low-risk HPV subtypes, among 
44 HC II positive samples, HPV 6 was detected in 8 cases and 
HPV 11 was detected in 2 cases. 81.8% (36/44) of the HC II posi-
tive samples had subtypes that could not be determined. This 
may be due to that the PCR primers used in our study were only 
for HPV subtypes 6 and 11, and thus the remaining subtypes 
could not be detected. 
 Because the clearance rate for low-risk HPV was higher than 
that for high-risk HPV, with a shorter duration of infection, the 
prevalence of low-risk HPV might reflect a pattern of new HPV 
infections (23). On the other hand, HPV seroprevalence is a 
good marker of cumulative HPV exposure, although due to a 
low seroconversion rate after HPV infection, HPV seropreva-
lence does not indicate the current state of HPV infection (8, 12). 
Worldwide, the seroprevalence of low-risk HPV varies accord-
ing to HPV subtype, age, and regional differences. Nonetheless, 
it has been reported to be 10%-20% (24, 25). The seroprevalence 
of low-risk HPV subtypes 6 and 11 was 9.4% among females 
aged 9-59 yr (the age-standardized prevalence was 9.6%), which 
was lower than those of western countries. In the present study, 
the seroprevalence of low-risk HPV subtypes 6 and 11 accord-
ing to age showed its highest peak in the 20s and a second peak 
in the 50s, similar to the age-specific pattern of the prevalence of 
HPV infection. It was observed in previous reports that general-
ly, as age increased, HPV seroprevalence also increased or main-
tained a plateau level (25, 26). Additionally, it has been reported 
that HPV prevalence reaches a peak within 5-10 yr of sexual de-
but and that HPV seroconversion occurs frequently between 6 
and 18 months of DNA detection (12, 27, 28). Therefore, we can 
infer that first exposure to HPV among Korean women is occur-
ring earlier, and that the sexual lives of middle-aged women have 
become more active.
 The concordance between low-risk HPV DNA positivity and 
seropositivity was poor. Only 12.5% of HPV 6 PCR-positive wom-
en were seropositive for HPV 6. In case of HPV 11, two PCR-pos-
itive samples had no antibody for HPV 11. This discrepancy can 
be explained by the effect of HPV-specific immune-evasion 
mechanism, waning of detectable antibodies, a long lag time 
required for seroconversion (29, 30).
 In regard to behavioral risk factors, there were significant dif-
ferences in seroprevalence of low-risk HPV by both lifetime 
number of sexual partners and history of STD. It had previously 
been reported that HPV seroprevalence is associated with the 
age of sexual debut, the lifetime number of sex partners, marital 
status, and education level (25, 31). 
 Although clinical trials has not demonstrated remarkable ef-
ficacy in prevention of invasive cervical cancer from HPV vacci-
nation, it has shown that the vaccine is almost 100% effective in 
preventing infection related to the vaccine-specific HPV geno-
types. According to previous studies, teenagers without sexual 
experience certainly benefit from HPV vaccination. Kim et al. 
reported that HPV vaccine is highly immunogenic and well tol-
erated in Korean girls aged 10-14 yr (32). Among sexually active 
women, cases where individuals were infected with all four 
types of HPV vaccine were rare. Therefore, even women infect-
ed with one or more HPV subtypes prior to vaccination can be 
protected from uninfected subtypes by vaccination. Consider-
ing that as women become older or more sexually active, the 
possibility of more sexual partners and the exposure to HPV in-
creases, most women could benefit from HPV vaccination. 
 There are limitations in our study. First, although the low-risk 
HPV group is often associated with low grade squamous intraep-
ithelial lesions and non-malignant genital tract lesions (genital 
warts), such correlation between the low-risk HPV positivity 
and cervical pathology was not analyzed in our study. Thereby, 
a further study is needed to monitor the presence and persis-
tence of cervical pathology in low-risk HPV infected women. 
Second, in our study, PCR assay was performed to classify low-
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risk HPV subtypes 6 and 11 among various HC II positive sam-
ples. It is possible that some false negative samples of HC II were 
missed while other low risk HPV types except HPV 6 and 11 could 
not have been detected. For these reasons, we may be underes-
timating the low-risk HPV prevalence in our study.
 In conclusion, our results confirm that the prevalence and 
seroprevalence of low-risk HPV tend to increase rapidly in their 
20s, when women are becoming sexually active. In order to 
achieve optimal efficacy, it would be reasonable to vaccinate 
women in their teens prior to HPV exposure.
 However, our study shows that seroprevalence reaches its 
peak earlier than it has been previously thought, implying that 
the pattern of sexual behavior among Korean teenagers is chang-
ing rapidly. Therefore, also considering the lag period of sero-
conversion, the optimal age for catch-up vaccination should be 
lowered. In addition, our results show that a second peak of both 
the prevalence and seroprevalence of low-risk HPV occurs in 
middle aged women. Also considering that the probability of 
women who are sexually active being infected with all four HPV 
vaccine types is low, it may be necessary to adjust the recom-
mended age of catch-up vaccination and discuss the vaccina-
tion strategy in middle aged woman. However, future research 
will be needed to define the clinical significance and natural 
history of seronegative infection of low-risk HPV. Our data will 
help to establish a policy to reduce an important fraction of dis-
ease burden of low-risk HPV 6 and 11 targeted by the quadriva-
lent vaccine and to monitor vaccine efficacy. 
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